TATAA Biocenter partners with Universal Sequencing Technology Corporation to offer Linked Long Read Sequencing Services
11 Jan 2023
GOTHENBURG, Sweden, Jan. 11, 2023 /PRNewswire/ -- TATAA Biocenter has partnered with Universal Sequencing Technology Corporation (UST) to offer full-service solutions for Long Read Sequencing Applications using UST TELL-Seq Linked Read technology.
TATAA Biocenter was founded in 2001 and is a leading provider of molecular services to the Advanced Therapies and Medical products (ATMP) industries in Europe and to the Cell and Gene Therapy industry in the United States.
UST's TELL-Seq technology, a transposase-based patent-pending linked-read library technology, enables short read 2nd generation NGS platforms, such as Illumina sequencers, to produce super long-range sequencing results (averaging linked-read molecule length greater than 40kb, up to and exceeding 200kb). A sequencing-ready library can be prepared in a PCR tube in ~3 hours with a simple workflow and basic lab equipment, which is simple, fast, and cost-effective. A unique feature of UST TELL-Seq is that it only requires ultra-low DNA input, 3-5ng for the human genome and 0.1-0.5ng for microbial genomes and target sequencing panels.
Dr. Aaron U. Levy, GM & Chief Commercial Officer of UST, who recently visited the TATAA Biocenter facility in Gothenburg, stated that he was impressed with the laboratory's setup, corporate culture, professionalism, and up-to-code superb sequencing services. Levy added that "TELL-Seq library technology is compatible with the range of Illumina sequencing platforms from benchtop like MiniSeq™ up to high-throughput NovaSeq™ 6000. The collaboration between UST and TATAA, based on the growing need for long-read results with very accurate short-read Illumina sequencers is speeding up the adoption of UST's super long-range TELL-Seq NGS library products among Illumina users in the US and all over the world."
With UST TELL-Seq library preparation kits and an Illumina sequencer, one can do de novo sequencing of microbial, animal, plant, and insect genomes, metagenomics, human genome phasing, and structural variation detection.
Mikael Kubista, the founder and CEO of TATAA Biocenter, stated, "The innovative TELL-Seq Linked-Read Technology for long-read sequencing is a most welcome complement to our service offerings. Our customers and sponsors will now gain additional advantages over their competitors through our broad range of qualified molecular services."
CONTACT:
Contact for more info:
Martin Cooke, TATAA Biocenter, Marketing & Comms Specialist.
Emaii: martin.cooke@tataa.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.